Contrary to expectation: Preserved renal function after using PD-1 Inhibitor Cemiplimab-rwlc in a kidney transplant recipient

Muhannad Leghrouz*, Svetomir N Markovic and Aleksandra Kukla

The use of immune checkpoint inhibitors in transplant recipients with malignancy is associated with the risk of graft failure due to acute rejection. There is limited literature regarding the use of Cemiplimab-rwlc (Libtayo) in kidney transplant patients. Here we present a case of using Cemiplimab-rwlc (Libtayo), a Programmed Death receptor-1 (PD-1) blocking antibody for locally advanced and metastatic Cutaneous Squamous Cell Carcinoma (CSCC), in a kidney transplant recipient.

Keywords:

Published on: Sep 8, 2022 Pages: 9-10

Full Text PDF Full Text HTML DOI: 10.17352/2640-7973.000020
CrossMark Publons Harvard Library HOLLIS Search IT Semantic Scholar Get Citation Base Search Scilit OAI-PMH ResearchGate Academic Microsoft GrowKudos Universite de Paris UW Libraries SJSU King Library SJSU King Library NUS Library McGill DET KGL BIBLiOTEK JCU Discovery Universidad De Lima WorldCat VU on WorldCat